Cathie Wood’s ARK sells Eli Lilly stock, buys Tempus AI and Coinbase

ARK ETFs sold 17,626 shares of Eli Lilly (LLY) for $24.2M and bought shares in Tempus AI (TEM) for $12M, Coinbase (COIN) for $6.3M, Circle (CRCL) for $6M, Pacific Biosciences (PACB) for $1.4M, and Robinhood (HOOD) for $1.3M. They also sold shares in Bullish (BLSH) for $6.8M and CareDx (CDNA) for $3.6M.

Original reporting
Published Oct 31, 2026, 12:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2026, 12:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LLY
Bearish
high confidence
Mentioned
$LLY · $TEM · $COIN · $CRCL · $PACB · $HOOD
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LLYBearishLow
01

Why it matters

The net effect is a reallocation from pharma to AI‑focused and crypto‑related assets.

02

Market read

Provides actionable data for traders monitoring fund flows and sector rotation.

03

What to watch

Potential upcoming earnings or clinical data could drive price moves independent of ARK trades.

Relevance 4/10Novelty 3/10Timing: today

Background

ARK's daily trade disclosures provide insight into its evolving investment thesis across sectors.

Company-level read

Ticker impact

$LLYBearishHigh confidence
Context

ARK sold 17,626 shares of Eli Lilly, reducing its stake.

Expected impact

likely downward pressure as the market prices in the sell.

Evidence & confidence

Large sell order from a high‑profile fund can push the stock lower in the short term.

$TEMBullishHigh confidence
Context

ARK bought 154,521 shares of Tempus AI across its ARKK and ARKG ETFs.

Expected impact

likely upward pressure as the market absorbs the purchase.

Evidence & confidence

Significant purchase by a well‑known growth fund may boost sentiment.

$COINBullishMedium confidence
Context

ARK added 39,418 shares of Coinbase to its ARKK, ARKW and ARKF ETFs.

Expected impact

potential modest upside as the fund signals confidence in the exchange.

Evidence & confidence

Fund buying can offset recent crypto volatility, but broader market sentiment remains mixed.

$CRCLBullishMedium confidence
Context

ARK purchased 74,894 shares of Circle Internet Group.

Expected impact

likely slight upward pressure.

Evidence & confidence

Circle’s exposure to stablecoins may benefit from ARK’s allocation.

$PACBBullishMedium confidence
Context

ARK bought 480,274 shares of Pacific Biosciences.

Expected impact

potential modest upside.

Evidence & confidence

Large share purchase signals confidence in genomics sector.

$HOODBullishMedium confidence
Context

ARK increased its stake in Robinhood with a purchase of 13,757 shares.

Expected impact

likely upward pressure.

Evidence & confidence

Continued buying by ARK may reinforce bullish sentiment.

$BLSHBearishHigh confidence
Context

ARK sold 238,373 shares of Bullish, exiting the position.

Expected impact

likely downward pressure.

Evidence & confidence

Large sell from a prominent fund can depress the stock.

$CDNABearishHigh confidence
Context

ARK reduced its holding in CareDx, selling 50,859 shares.

Expected impact

potential downside as the market absorbs the sell.

Evidence & confidence

Significant reduction by ARK may signal concerns about the biotech.

Market effects

Highlights ARK's shifting focus within biotech and AI‑driven healthcare.

Primarily U.S. equity market; no direct regional effect.

Limited to investors tracking ARK's portfolio allocations.

Counterpoint

Some may view ARK's exits as a signal to short the sold stocks.

Key entities

  • Cathie Wood

    Founder of ARK Invest, whose fund actions influence market sentiment.

Related articles

$LLYMed

Lilly reveals how much weight patients lost in latest obesity drug trials

Eli Lilly & Co. reported data from obesity drug trials at ObesityWeek 2026. EloraTZP showed 23.3% weight loss at 28 weeks, 60% of patients achieved non-obese BMI at 48 weeks, and 77% reached normal blood glucose levels. Zepbound reduced BMI by 21.4% at 72 weeks in teens. Both drugs improved quality of life. Lilly also claimed retatrutide outperformed Novo Nordisk's Ozempic in weight reduction and blood sugar control.

$LLYMedAI 9/10

Lilly presents obesity drug trial results at ObesityWeek 2026

Eli Lilly (NYSE:LLY) presented obesity and diabetes drug trial results at ObesityWeek 2026. EloraTZP showed 23.3% weight loss and 2.9% A1C reduction. Retatrutide reduced sleep apnea events by 60.6% and knee osteoarthritis pain by 73.1%. Zepbound reduced adolescent BMI by 21.4%. Foundayo users found it convenient. Eloralintide reduced food cravings and alcohol consumption.